

Caterina Scuderi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5895887/publications.pdf>

Version: 2024-02-01

59
papers

3,077
citations

172457
29
h-index

161849
54
g-index

59
all docs

59
docs citations

59
times ranked

3955
citing authors

#	ARTICLE	IF	CITATIONS
1	Cannabidiol Reduces A β ² -Induced Neuroinflammation and Promotes Hippocampal Neurogenesis through PPAR γ ³ Involvement. PLoS ONE, 2011, 6, e28668.	2.5	312
2	Cannabidiol in vivo blunts β -amyloid induced neuroinflammation by suppressing IL-1 β and iNOS expression. British Journal of Pharmacology, 2007, 151, 1272-1279.	5.4	235
3	Targeting neuroinflammation in Alzheimer's disease. Journal of Inflammation Research, 2016, Volume 9, 199-208.	3.5	198
4	Cannabidiol: A Promising Drug for Neurodegenerative Disorders?. CNS Neuroscience and Therapeutics, 2009, 15, 65-75.	3.9	179
5	Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders. Phytotherapy Research, 2009, 23, 597-602.	5.8	149
6	Cannabidiol Reduces Intestinal Inflammation through the Control of Neuroimmune Axis. PLoS ONE, 2011, 6, e28159.	2.5	134
7	Cannabidiol Promotes Amyloid Precursor Protein Ubiquitination and Reduction of Beta Amyloid Expression in SHSY5Y APP+ Cells Through PPAR γ ³ Involvement. Phytotherapy Research, 2014, 28, 1007-1013.	5.8	124
8	Genomic and functional profiling of human Down syndrome neural progenitors implicates S100B and aquaporin 4 in cell injury. Human Molecular Genetics, 2008, 17, 440-457.	2.9	101
9	Palmitoylethanolamide exerts neuroprotective effects in mixed neuroglial cultures and organotypic hippocampal slices via peroxisome proliferator-activated receptor- α . Journal of Neuroinflammation, 2012, 9, 49.	7.2	97
10	Palmitoylethanolamide counteracts reactive astrogliosis induced by β -amyloid peptide. Journal of Cellular and Molecular Medicine, 2011, 15, 2664-2674.	3.6	90
11	S100B induces tau protein hyperphosphorylation via Dickkopf-1 up-regulation and disrupts the Wnt pathway in human neural stem cells. Journal of Cellular and Molecular Medicine, 2008, 12, 914-927.	3.6	81
12	Cannabidiol in Inflammatory Bowel Diseases: A Brief Overview. Phytotherapy Research, 2013, 27, 633-636.	5.8	81
13	Palmitoylethanolamide controls reactive gliosis and exerts neuroprotective functions in a rat model of Alzheimer's disease. Cell Death and Disease, 2014, 5, e1419-e1419.	6.3	79
14	S100B and APP Promote a Gliocentric Shift and Impaired Neurogenesis in Down Syndrome Neural Progenitors. PLoS ONE, 2011, 6, e22126.	2.5	73
15	Opposing Control of Cannabinoid Receptor Stimulation on Amyloid- β -Induced Reactive Gliosis: In Vitro and in Vivo Evidence. Journal of Pharmacology and Experimental Therapeutics, 2007, 322, 1144-1152.	2.5	72
16	Does neuroinflammation turn on the flame in Alzheimer's disease? Focus on astrocytes. Frontiers in Neuroscience, 2015, 9, 259.	2.8	72
17	CB1 receptor selective activation inhibits β -amyloid-induced iNOS protein expression in C6 cells and subsequently blunts tau protein hyperphosphorylation in co-cultured neurons. Neuroscience Letters, 2006, 404, 342-346.	2.1	68
18	Ultramicrosized palmitoylethanolamide rescues learning and memory impairments in a triple transgenic mouse model of Alzheimer's disease by exerting anti-inflammatory and neuroprotective effects. Translational Psychiatry, 2018, 8, 32.	4.8	64

#	ARTICLE	IF	CITATIONS
19	Neuroglia in the autistic brain: evidence from a preclinical model. <i>Molecular Autism</i> , 2018, 9, 66.	4.9	63
20	Sirtuin modulators control reactive gliosis in an in vitro model of Alzheimer's disease. <i>Frontiers in Pharmacology</i> , 2014, 5, 89.	3.5	56
21	Altered Waste Disposal System in Aging and Alzheimer's Disease: Focus on Astrocytic Aquaporin-4. <i>Frontiers in Pharmacology</i> , 2020, 10, 1656.	3.5	50
22	Altered Brain Cholesterol/Isoprenoid Metabolism in a Rat Model of Autism Spectrum Disorders. <i>Neuroscience</i> , 2018, 372, 27-37.	2.3	48
23	Palmitoylethanolamide Dampens Reactive Astroglia and Improves Neuronal Trophic Support in a Triple Transgenic Model of Alzheimer's Disease: <i>In Vitro</i> and <i>In Vivo</i> Evidence. <i>Oxidative Medicine and Cellular Longevity</i> , 2018, 2018, 1-14.	4.0	48
24	Neuroglial Roots of Neurodegenerative Diseases: Therapeutic Potential of Palmitoylethanolamide in Models of Alzheimer's Disease. <i>CNS and Neurological Disorders - Drug Targets</i> , 2013, 12, 62-69.	1.4	45
25	Cannabinoid CB1 receptor stimulation affords neuroprotection in MPTP-induced neurotoxicity by attenuating S100B up-regulation in vitro. <i>Journal of Molecular Medicine</i> , 2007, 85, 1379-1392.	3.9	41
26	Early intrathecal infusion of everolimus restores cognitive function and mood in a murine model of Alzheimer's disease. <i>Experimental Neurology</i> , 2019, 311, 88-105.	4.1	41
27	Role of astrocytes in major neurological disorders: The evidence and implications. <i>IUBMB Life</i> , 2013, 65, 957-961.	3.4	39
28	An Animal Model of Alzheimer Disease Based on the Intrahippocampal Injection of Amyloid β -Peptide (1-42). <i>Methods in Molecular Biology</i> , 2018, 1727, 343-352.	0.9	37
29	Oleylethanolamide decreases frustration stress-induced binge-like eating in female rats: a novel potential treatment for binge-eating disorder. <i>Neuropsychopharmacology</i> , 2020, 45, 1931-1941.	5.4	36
30	Astrocyte Function Is Affected by Aging and Not Alzheimer's Disease: A Preliminary Investigation in Hippocampi of 3xTg-AD Mice. <i>Frontiers in Pharmacology</i> , 2019, 10, 644.	3.5	32
31	The antiprotozoal drug pentamidine ameliorates experimentally induced acute colitis in mice. <i>Journal of Neuroinflammation</i> , 2012, 9, 277.	7.2	29
32	S100B-p53 disengagement by pentamidine promotes apoptosis and inhibits cellular migration via aquaporin-4 and metalloproteinase-2 inhibition in C6 glioma cells. <i>Oncology Letters</i> , 2015, 9, 2864-2870.	1.8	28
33	Palmitoylethanolamide Regulates Production of Pro-Angiogenic Mediators in a Model of β Amyloid-Induced Astroglia <i>In Vitro</i> . <i>CNS and Neurological Disorders - Drug Targets</i> , 2015, 14, 828-837.	1.4	25
34	Looking for a Treatment for the Early Stage of Alzheimer's Disease: Preclinical Evidence with Co-Ultramicronized Palmitoylethanolamide and Luteolin. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3802.	4.1	24
35	Astrocytes: The Housekeepers and Guardians of the CNS. <i>Advances in Neurobiology</i> , 2021, 26, 21-53.	1.8	19
36	The prokineticin receptor antagonist PC1 rescues memory impairment induced by β amyloid administration through the modulation of prokineticin system. <i>Neuropharmacology</i> , 2019, 158, 107739.	4.1	18

#	ARTICLE	IF	CITATIONS
37	The role of neuroglia in autism spectrum disorders. Progress in Molecular Biology and Translational Science, 2020, 173, 301-330.	1.7	18
38	Astrocyte: An Innovative Approach for Alzheimer's Disease Therapy. Current Pharmaceutical Design, 2018, 23, 4979-4989.	1.9	17
39	Acute Ketamine Facilitates Fear Memory Extinction in a Rat Model of PTSD Along With Restoring Glutamatergic Alterations and Dendritic Atrophy in the Prefrontal Cortex. Frontiers in Pharmacology, 2022, 13, 759626.	3.5	17
40	Alternative Targets to Fight Alzheimer's Disease: Focus on Astrocytes. Biomolecules, 2021, 11, 600.	4.0	16
41	Targeting the Oxytocinergic System: A Possible Pharmacological Strategy for the Treatment of Inflammation Occurring in Different Chronic Diseases. International Journal of Molecular Sciences, 2021, 22, 10250.	4.1	13
42	Co-Ultramicronized Palmitoylethanolamide/Luteolin Restores Oligodendrocyte Homeostasis via Peroxisome Proliferator-Activated Receptor- α in an In Vitro Model of Alzheimer's Disease. Biomedicines, 2022, 10, 1236.	3.2	10
43	Differential Cannabinoid Receptor Expression during Reactive Gliosis: a Possible Implication for a Nonpsychotropic Neuroprotection. Scientific World Journal, The, 2009, 9, 229-235.	2.1	9
44	Neuroinflammation in Alzheimer's Disease: Friend or Foe?. FASEB Journal, 2020, 34, 1-1.	0.5	9
45	Neuroglia in Psychiatric Disorders. Advances in Neurobiology, 2021, 26, 3-19.	1.8	9
46	Principles of Astroglipathology. Advances in Neurobiology, 2021, 26, 55-73.	1.8	8
47	Post-COVID-19 neuropsychiatric syndrome: Is maladaptive glial recovery to blame?. Acta Physiologica, 2021, 233, e13717.	3.8	7
48	Systemic Inflammation and Astrocyte Reactivity in the Neuropsychiatric Sequelae of COVID-19: Focus on Autism Spectrum Disorders. Frontiers in Cellular Neuroscience, 2021, 15, 748136.	3.7	7
49	Astroglial Serotonin Receptors as the Central Target of Classic Antidepressants. Advances in Neurobiology, 2021, 26, 317-347.	1.8	7
50	Sorafenib Chemosensitization by Caryophyllane Sesquiterpenes in Liver, Biliary, and Pancreatic Cancer Cells: The Role of STAT3/ABC Transporter Axis. Pharmaceutics, 2022, 14, 1264.	4.5	7
51	Are Retinoids a Promise for Alzheimer's Disease Management?. Current Medicinal Chemistry, 2012, 19, 6119-6125.	2.4	6
52	Are Anti-Angiogenic Drugs Useful in Neurodegenerative Disorders?. CNS and Neurological Disorders - Drug Targets, 2010, 9, 807-812.	1.4	6
53	How useful are biomarkers for the diagnosis of Alzheimer's disease and especially for its therapy?. Neural Regeneration Research, 2022, 17, 2205.	3.0	6
54	Editorial: Neuroglia Molecular Mechanisms in Psychiatric Disorders. Frontiers in Molecular Neuroscience, 2018, 11, 407.	2.9	5

#	ARTICLE	IF	CITATIONS
55	Successful and Unsuccessful Brain Aging in Pets: Pathophysiological Mechanisms behind Clinical Signs and Potential Benefits from Palmitoylethanolamide Nutritional Intervention. <i>Animals</i> , 2021, 11, 2584.	2.3	5
56	Effects of Ultramicrosized Palmitoylethanolamide on Mitochondrial Bioenergetics, Cerebral Metabolism, and Glutamatergic Transmission: An Integrated Approach in a Triple Transgenic Mouse Model of Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, .	3.4	4
57	How could retinoids fit into Alzheimer's therapy?. <i>Drugs of the Future</i> , 2016, 41, 0015.	0.1	3
58	Preparation of Rat Hippocampal Organotypic Cultures and Application to Study Amyloid β -Peptide Toxicity. <i>Methods in Molecular Biology</i> , 2018, 1727, 333-341.	0.9	0
59	Astrocyte-neuron interplay in Alzheimer's disease: evidence from an innovative and promising pharmacological manipulation in a triple transgenic model of the disease. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018, WCP2018, PO1-1-65.	0.0	0